Expensive HIV medications are likely being targeted for resale on the black market, according to a new report from a federal watchdog. The report explained that the patterns the agency detected could mean patients were diverting the drugs for sale on the black market or that pharmacies were fraudulently billing Medicare for drugs that were never dispensed.
In August, federal investigators detailed $32 million in suspicious charges to Medicare’s Part D program for HIV drugs for beneficiaries with no evidence of an HIV infection in their Medicare records (http://1.usa.gov/1oEfYgj). Earlier this year, the Community Access National Network (CANN), a group that supports access to HIV care, and the Partnership for Safe Medicines, a nonprofit organization targeting counterfeit medication, published a document (http://bit.ly/1stOjhQ) alerting clinicians and patients to evidence that HIV medications were being resold illegally.
Kuehn BM. Reports: HIV Drugs Targeted for Black Market. JAMA. 2014;312(11):1086–1087. doi:10.1001/jama.2014.11153
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: